All articles tagged with #medical research
The FDA has approved Roche’s blood test that detects brain amyloid, a biomarker for Alzheimer’s disease, to help diagnose suspected cases. It is not intended for routine screening and could be easier to administer in primary care than PET scans or cerebrospinal fluid tests, potentially enabling earlier, less invasive confirmation for patients and families.
The Washington Post’s Editorial Board argues that the Moderna-Merck cancer vaccine—a breakthrough driven by advances in genomics and computing—shows how cutting-edge medical tech can overcome resistance to new science, offering life-saving hope to the 100,000+ Americans affected by skin cancer annually and the more than 8,000 who die each year.
A study suggests replacing sitting with short bursts of movement—three minutes of vigorous activity (such as stair climbs) or a 30-second stand at your desk—could trim the risk of 13 cancers by up to about 7%, based on data from roughly 60,000 people, highlighting how small, regular movements during the day can aid cancer prevention.
A real-world Veterans Health Administration study of 4,890 men with metastatic hormone-sensitive prostate cancer found that achieving a PSA below 0.2 ng/mL within 9 months of starting testosterone-deprivation therapy was associated with a 54% lower risk of death over a median follow-up of about 2 years. Notably, patients who only achieved a 90% PSA decline without hitting the 0.2 ng/mL threshold did not see a survival benefit. The findings suggest targeting PSA <0.2 ng/mL as a key treatment-success metric and indicate that more aggressive therapy may be warranted for those who do not reach this level; adding another drug to further block testosterone improved odds of reaching the threshold.
Emerging research suggests some cognitive training can yield measurable brain changes and may lower dementia risk, but experts warn against hype and call for rigorous, individualized studies noting potential gender differences in benefits.
UCLA researchers report that pairing DNA-damaging antibody-drug conjugates (ADCs) with BCL-XL inhibitors boosts cancer cell death and slows tumor growth in metastatic castration-resistant prostate cancer, shown in lab and mouse models. The work highlights co-targeting proteins B7-H3, PSMA, and STEAP1 to reach more cancer cells and notes that tumors with intact TP53 respond best, suggesting genetic testing could guide patient selection. The study provides a framework for next-generation, multi-payload, multi-target ADCs to improve durability of prostate cancer therapies, pending clinical trials.
An international team led by the Medical University of Vienna report that Teclistamab, a cancer drug, drastically reduced antibodies against donor tissue in a dialysis-dependent patient with a zero probability of finding a compatible donor, enabling a successful kidney transplant after 31 weeks of therapy; the patient is thriving and the approach could shift transplant medicine, with broader studies planned to assess safety and applicability to other organ transplants.
Keith Thomas, paralyzed from the chest down after a 2020 pool accident, regained arm and hand control plus tactile sensation through a double neural bypass that links his brain to arm nerves and uses finger sensors. After 35 weeks of training, arm strength improved 86% on the right and 62% on the left, enabling actions like scratching his nose and gripping objects, and letting him feel things like his dog’s fur. The findings, detailed in Nature, highlight the potential of brain–computer interface technology to restore movement and touch for people with paralysis.
Smell loss can signal neurodegenerative diseases like Alzheimer's and Parkinson's years before other symptoms, and while smell training might improve olfactory function and potentially cognitive health, experts say more research is needed to confirm brain benefits.
A two-drug combo (chlorpromazine and promethazine) lowers body temperature in mice by dilating skin vessels and slowing metabolism, reducing brain tissue death and improving outcomes after induced stroke; a human trial found the therapy safe but not effective at the tested doses, suggesting potential to extend the treatment window if optimized.
Monash University researchers used Cu(ATSM), a copper-delivery compound, to repair the brain’s blood–brain barrier by increasing the P-glycoprotein clearance pumps, which reduced toxic amyloid-beta by about 42% and improved long-term spatial memory by roughly 44% in an APP/PS1 mouse model over 56 days, suggesting copper-based biometal therapy could be a promising route for early symptomatic Alzheimer's disease with potential for quicker human testing due to prior safety evaluations; future work aims to map the precise clearance mechanisms and pathways.
A scientist learns he has Huntington’s disease, a genetic brain disorder caused by CAG repeats, and launches a personal quest to find treatments, a mission that reflects a broader, large-scale effort to develop therapies for Huntington’s and other brain diseases.
A landmark trial of the KRAS-targeting pill daraxonrasib shows pancreatic cancer patients living about twice as long as with standard chemotherapy and with tumors kept in check longer, a potential breakthrough developed by Revolution Medicines that has prompted FDA expanded access while a full review continues.
A small study of 13 teens and young women on GLP-1 drugs (including Ozempic) found unexpected brain changes, suggesting these medications may reshape neural circuits related to appetite, emotion and motivation; while findings hint at possible implications for addiction, cognition and aging-related diseases, researchers caution that the brain effects are preliminary and require further study.
A large study suggests that the optimal nightly sleep is about 6.4 to 7.8 hours. Sleeping too little or too much is associated with accelerated aging across multiple organs, and the piece offers tips to help people hit the “just right” amount.